This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, L. A. Articles by Moyer, J. D. Search for Related Content PubMed PubMed Citation Articles by Cohen, L. A. Articles by Moyer, J. D.

LAS, a Novel Selective Estrogen Receptor Modulator with Chemopreventive and Therapeutic Activity in the N-Nitroso-N-methylurea-induced Rat Mammary Tumor Model¹

American Health Foundation, Valhalla, New York 10595 [L. A. C., B. P., C-X. W., C. A.], and Pfizer Global Research and Development, Groton, Connecticut 06340 [L. Y., J. D. M.]

The N-nitroso-N-methylurea-induced rat mammary tumor model was used to conduct two types of studies: a prevention study designed to test the ability of the novel selective estrogen receptor modulator lasofoxifene (LAS) to inhibit the development of mammary tumors, and a treatment study designed to test the inhibitory effect of LAS on the growth of established tumors. The prevention study indicated that LAS markedly delayed the emergence of N-nitroso-N-methylurea-induced tumors to an extent similar to that obtained by the established antiestrogen tamoxifen (TAM). At the highest dose administered, both TAM and LAS reduced tumor incidence by 75% and total tumor number by 90% relative to the controls. LAS also reduced the multiplicity of tumors, i.e., the mean number of tumors per rat, and resulted in substantially smaller total tumor burden. In the treatment study, LAS significantly inhibited tumor growth compared with the controls. In addition, whereas none of the untreated tumors regressed completely over the experimental period, 40% of LAS-treated tumors regressed by >50% at the highest dose (10 mg/kg daily). The results of this study in a rat mammary tumor model indicate that LAS has both chemopreventive and chemotherapeutic effects quantitatively comparable with those of TAM.

This article has been cited by other articles:

				R. A Moller, J. M Fisher, A. E Taylor, S. Kolluri, M. J Gardner, R S. Obach, and R. L Walsky Effects of Steady-State Lasofoxifene on CYP2D6- and CYP2E1-Mediated Metabolism Ann. Pharmacother., January 1, 2006; 40(1): 32 - 37. [Abstract] [Full Text] [PDF]

				M. B. Sporn Arzoxifene: A Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer: Commentary re C. J. Fabian et al., Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator. Clin Cancer Res 2004;10:5403-17. Clin. Cancer Res., August 15, 2004; 10(16): 5313 - 5315. [Full Text] [PDF]

				H. Z. Ke, G. L. Foley, H. A. Simmons, V. Shen, and D. D. Thompson Long-Term Treatment of Lasofoxifene Preserves Bone Mass and Bone Strength and Does Not Adversely Affect the Uterus in Ovariectomized Rats Endocrinology, April 1, 2004; 145(4): 1996 - 2005. [Abstract] [Full Text] [PDF]